Kornimate/medical-research-clean huggingface dataset:
auriculotherapy and acupuncture's treatment for chemotherapy-induced nausea and vomiting (cinv)

Conditions: Nausea; Vomiting

Summary: the management of chemotherapy-induced nausea and vomiting (cinv) has evolved in recent years and became less frequent. cinv include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4 days after chemotherapy) nausea and vomiting. preventive treatment, such as glucocorticoids, 5-hydroxytryptamine type 3 (5-ht3) receptor antagonists and neurokinin 1 (nk1) receptor antagonists, are administered according to the classification in 4 grades of expected cinv * very low: \<10% occurrence of cinv; * low: 10 to 30% occurrence of cinv; * average: 30 to 90% occurrence of cinv; * high: \> 90% occurrence of cinv. these treatments have been the subject of recommendations. despite these available treatments, some patients still complain of vomiting, or more frequently nausea and loss of appetite. meanwhile, chinese acupuncture has proven effective on the prevention of cinv as complementary treatment, mainly in the acute phase and to a lesser extent in the delayed phase. the most common points are pericardium 6 (wrist) treated with conventional acupuncture needles, electro-acupuncture or acupressure. auriculotherapy (ear acupuncture) has proven effective on nausea of pregnancy and postoperative nausea, but, to our knowledge, there are no studies published on the effect of auriculotherapy on cinv. these complementary treatments have virtually no side effects. in our institution, a simple treatment of acupuncture (2 points pericardium 6 treated) and auriculotherapy (2 auricular point treated) is regularly use in patients who present cinv despite preventive treatment and most of them are relieved. the investigators propose a clinical trial in this population to assess symptoms improvement in patients presenting cinv after their first administration of chemotherapy despite adapted preventive treatment. experimental treatment with semi-permanent needles takes place during administration of the second session of chemotherapy. cinv are evaluated through the (mat) score that measures the frequency and intensity of nausea and vomiting in the 24 hours following the session and during the 4 days after administration chemotherapy. multinational association of supportive care in cancer antiemesis tool (mascc), http://www.mascc.org/.


Eligibility criteria:
inclusion criteria: * out-patient chemotherapy * treated nausea vomiting induced by chemotherapy (nvic) exclusion criteria: * prior treatment with acupuncture and or auriculotherapy for nvic * no conventional treatment for nvic like phytotherapy and homeopathy * radiotherapy (five days before and 5 days after chemotherapy) * mri in the five days after first visit
predictive role of strem in endovascular thrombectomy outcomes

Conditions: Acute Ischemic Stroke

Summary: soluble triggering receptor expressed on myeloid cells (strem), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. this study is to investigatethe prognostic roles of strem (strem1 and strem2) in patients with ischemic stroke who underwent endovascular thrombectomy (evt).

for acute ischemic stroke, the current treatment strategy involves timely recanalization by intravenous thrombolysis and endovascular thrombectomy (evt). patients receiving evt are more likely to achieve successful revascularization and long--term functional independence compared with those receiving standard medical treatment.1 in patients receiving evt, significant predictors of a favorable functional outcome include minor initial stroke severity, successful recanalization, and shorter onset--to--treatment time. however, unfavorable outcomes can occur even after early successful recanalization in some cases.triggering receptors expressed on myeloid cells (trem-1 and trem-2) are a familyof receptors involved in the immune system expressed on a variety of innate cells of the myeloid lineage, including microglia. strem, which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. we enrolled adult patients with stroke who received evt, with blood sampling immediately before (t1) and after evt (t2), and at 24 hours after evt (t3). non--stroke controls and patients with non--evt stroke were also enrolled. the plasma concentration of strem1 and strem2 were analyzed by elisa. the medical information, image findings and levels of plasma strem1 and strem2 were analyzed to clarify the association with poor functional outcome (modified rankin scale 4-6) at 3 months after stroke.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old. * patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment. exclusion criteria: * impossibility of getting a blood sample. * impossibility of performing the test (invalid results). * refusal to provide the informed consent by the patient/relative.

Keywords: thrombectomy soluble trem-1 soluble trem-2
phase 2 study of glesatinib, sitravatinib or mocetinostat in combination with nivolumab in non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (tki) that primarily targets the axl and mesenchymal-epithelial transition (met) receptors. sitravatinib is an orally-available, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (rtks) including met, axl, mertk, vegfr family, pdgfr family, kit, flt3, trk family, ret, ddr2 and selected eph family members. mocetinostat is an orally administered histone deacetylase (hdac) inhibitor. nivolumab is a human igg monoclonal antibody that binds to the programmed cell death-1(pd-1) receptor and blocks its interaction with programmed cell death ligand-1 (pd-l1) and pd-l2, releasing pd-1 pathway-mediated inhibition of the immune response including anti-tumor immune response. combining an immunotherapeutic pd-l1 checkpoint inhibitor with an agent that has both immune modulatory and antitumor properties could enhance the antitumor efficacy observed with either agent alone. the study will begin with a lead-in dose escalation evaluation of two dose levels of each investigational agent in combination with nivolumab. following completion of the lead-in dose escalation, enrollment into the phase 2 study will proceed.

Eligibility criteria:
inclusion criteria: * diagnosis of non-small cell lung cancer. * prior treatment with a checkpoint inhibitor (as appropriate per cohort) * adequate bone marrow and organ function exclusion criteria: * uncontrolled tumor in the brain * unacceptable toxicity with prior checkpoint inhibitor * impaired heart function
aspirin for prevention of preeclampsia in healthy, nulliparous obese and overweight pregnant women

Conditions: Preeclampsia

Summary: preeclampsia is a pregnancy-specific syndrome that affects 3 - 5% of pregnancies. it is one of the main causes of maternal, fetal and neonatal morbidity and mortality, resulting in approximately 40,000 maternal deaths worldwide each year. fortunately, preeclampsia-related deaths have been reduced remarkably in recent decades thanks to improvements in antenatal care and therapeutic interventions, and prophylactic use of low-dose aspirin in women who are at a higher risk of developing preeclampsia. effective prevention is rarely available for obstetric complications. aspirin is one of them. several meta-analyses456 suggested that aspirin prescription reduced the risk of preeclampsia and fetal growth restriction by 40-50% in an aspirin-dose-response pattern.

preterm preeclampsia is an important cause of maternal and perinatal death and complications. it is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. in a meta-analysis of individual-participant data from the trials, the effect of aspirin was not affected by the gestational age at the onset of therapy. in contrast, other meta-analyses showed that aspirin started at or before 16 weeks of gestation resulted in halving the rates of preeclampsia, fetal growth restriction, and perinatal death, whereas aspirin started after 16 weeks of gestation did not have a significant benefit. in addition, the beneficial effect of aspirin that was started at or before 16 weeks of gestation was dose-dependent, with a greater reduction in the incidence of preeclampsia being associated with a daily dose of aspirin of 100 mg or more. this will be a randomized control trial to estimate the efficacy of two doses (81 mg versus 162 mg) of aspirin for prevention of preeclampsia in healthy, nulliparous obese and overweight pregnant women identified in the first trimester.

Eligibility criteria:
inclusion criteria: * healthy, nulliparous obese and overweight pregnant women identified in the first trimester. * give written informed consent. exclusion criteria: * multiple gestations, * fetal aneuploidy * major fetal structural anomaly * bleeding disorder * allergy to aspirin * women already on aspirin or heparin.

Keywords: preeclampsia low dose aspirin high risk pregnancy
audiobook application in patients receiving hemodialysis treatment

Conditions: Hemodialysis

Summary: this research will be conducted to evaluate the effects of audio book application on anxiety, depression and quality of life in patients receiving hemodialysis treatment.

hemodialysis is an extracorporeal blood purification technique used to remove accumulated metabolic waste products in patients and is a frequently used treatment method in patients with end-stage renal disease. although hemodialysis, which is one of the treatment of end-stage renal disease, prolongs life, it can also lead to various psychological disorders such as depression, anxiety and severe stress. psychological disorders and depression in dialysis patients often manifest as a response to loss of ability to work and earn an income, decreased energy, decreased sexual function, other limitations caused by physical disability, and reduced life expectancy. depression is the most common psychopathological condition in patients with end-stage renal disease. the rate of depressive symptoms among dialysis patients is high and its prevalence is up to 43%, and it is stated that it has a significant effect on quality of life. the psychological and somatic effects of depression can complicate the course of the chronic disease. reading books is one of the tools to heal mental disorders. some individuals cannot read on their own due to aging, poor eyesight, or lack of literacy. an audiobook is a recording of a book read by an author, actor, celebrity, or amateur. audiobooks are recommended for their friendliness, comfort, and emotional impact. audiobooks are recommended to increase the quality of life of individuals and to protect social health. this research will be conducted to evaluate the effects of audio book application on anxiety, depression and quality of life in patients receiving hemodialysis treatment. patient information form, hospital anxiety depression scale, sf-36 quality of life scale will be used to collect research data.

Eligibility criteria:
inclusion criteria: * over 18 years old, * receiving hemodialysis treatment for six months or longer, * receiving hemodialysis treatment three times a week, * no problem with the sense of hearing, * has no handicap in answering the questions physically and mentally, * no verbal communication disability (hearing and speaking), * can understand turkish, * not having been diagnosed with a mental illness, * patients willing to participate in the study will be recruited exclusion criteria: * those who want to withdraw from the research

Keywords: anxiety depression quality of life nurse audio book
effects of labetalol on human cocaine use - 8

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.

the goal of this study was to investigate the safety and utility of labetalol an alpha and beta adrenergic block, for cocaine dependence in humans. a total of 12 subjects were enrolled in this double blind, placebo controlled outpatient study. after baseline measures are obtained, three experimental sessions were held at least 2 days apart. subjects were administered a single low (100 mg) or high dose of labetalol (200mg) or placebo on each of 3 experimental sessions. the labetalol doses were given in ascending order and the placebo treatment were randomly inserted into the sequence. a single dose of smoked cocaine (0.4 mg/kg) was administered 2 hrs after labetalol or placebo treatment. during the sessions, several subjective, behavioral and physiological measures were obtained.

Eligibility criteria:
inclusion criteria: male/female ages 20-55. history of smoked or intravenous cocaine use on the average of at least once a week over a six month period. current history of good health and normal ekg. not pregnant as determined by pregnancy screening nor breat feeding and using acceptable birth control methods (e.g. birth control pills diaphragm, condoms, plus foam) during the study. exclusion criteria: current problems with major psychiatric illnesses including bipolar disorder, schizophrenia, or anxiety disorders. current dependence on alcohol or on durgs other than cocaine. history of major medical illnesses including asthma and chronic obstructive pulmonary disease. currently on a drug related parole or probation. treated for chemical dependency within the past 6 months.

Keywords: cocaine dependence
effects of niaspan™ on high-density lipoprotein (hdl) in healthy male subjects (0000-069)

Conditions: Dyslipidemia

Summary: this study will evaluate whether chronic dosing with niaspan™ increases reverse cholesterol transport, high-density lipoprotein cholesterol (hdl-c) levels, and fecal excretion of cholesterol.


Eligibility criteria:
inclusion criteria: * healthy male subjects exclusion criteria : * subject has a history of stroke, chronic seizures, or major neurological disorder * subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
bevacizumab for neovascular age-related macular degeneration

Conditions: Exudative Age-related Macular Degeneration

Summary: age-related macular degeneration (amd) is one of primary blinding eye disease among people over 65 years in china. the anti-vegf antibody treatment is proved useful for neovascular age-related macular degeneration (namd) by many studies. bevacizumab is the only available low-cost type of anti-vegf drug currently in china. this study is a multi-center, randomized trial of bevacizumab effective dose and safety for namd. this study is to explore the effective therapeutic approach that the majority of patients in china can bear establishing a suitable treatment for china.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of neovascular age-related macular degeneration * signed informed consent exclusion criteria: * no other ocular fundus diseases

Keywords: neovascular age-related macular degeneration bevacizumab multicenter randomized study
effects of tnf-alpha antagonism (etanercept) in patients with the metabolic syndrome and psoriasis

Conditions: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension

Summary: people with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. the purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. people with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol.

people with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. the purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. people with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol. insulin resistance means that the body does not respond well to the insulin in your blood. therefore, both blood levels of insulin and glucose (sugar) are high. this causes inflammation (irritation) in the body. inflammation can cause an unhealthy response in your body and blood vessels, and can lead to blockages in the heart and other vessels. tnf-alpha is a substance made by fat and inflammatory cells that helps cause inflammatory reactions. tnf-alpha is thought to be important in causing psoriasis. the drug etanercept blocks tnf-alpha's actions, and has been approved by the food and drug administration (fda) for the treatment of psoriasis. we think that etanercept may also reduce the inflammation associated with metabolic syndrome and decrease the risk of heart disease. all subjects in this study will receive etanercept.

Eligibility criteria:
inclusion criteria: 1. age \> 18 2. subject willing and able to give informed consent. 3. adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 4. pasi \> 10 and bsa affected with psoriasis \> 10. 5. abdominal obesity defined by waist hip ratio \> 0.90 for men and \> 0.85 for women and bmi ³ 30 kg/m2 exclusion criteria: * on insulin or other diabetes (anti-hyperglycemic) medication * congestive heart failure * heart attack, stroke or transient ischemic attack in last 3 months * unstable angina * pulmonary disease requiring oxygen * sle, optic neuritis, transverse myelitis, epilepsy * positive ppd * scheduled for upcoming surgery * known immunosuppression (for example, hiv) * known autoimmune disease * hepatitis b or hepatitis c * pregnant or nursing * renal insufficiency (creatinine \>1.5) * latex allergy * use of live vaccination in past 90 days * organ transplantation * history of severe infection * history of malignancy (except cured non-melanoma skin cancer)

Keywords: psoriasis metabolic syndrome syndrome x diabetes insulin resistance obesity hypertension hyperlipidemia hypercholesterolemia
the effects of exogenous ketosis on ultra-endurance recovery and performance

Conditions: Exogenous Ketosis; Endurance Cycling Performance; Fatigue; Muscle, Heart; Fatigue, Mental

Summary: the study aims to investigate the effects of post-exercise and pre-sleep ketosis via oral ketone ester supplementation on physical and mental recovery during a multi-day cycling stage race.

ultra-endurance events are becoming increasing popular. participation in the multi-day events adds a lot of physical and mental strain on the body, while the athletes are still required to perform. without appropriate recovery the athletes are at increased risk of overreaching, injury, or illness. therefore, the purpose of the study is to create a better understanding of the exercise fatigue experienced during ultra-endurance performance and the role intermittent exogenous ketosis (iek) plays in reducing the amount of fatigue to maintain performance during multi-day racing and lower the risk of injury and illness. participants will first compete in a 8-day simulated stage race performed on taxc trainers and then we will conduct a field study during the absa cape epic a 8-day mountain bike stage race. immediately following each stage and 30-mins before bed the participants will consume either a ketone ester and taste-match placebo drink. during the race the following variables will be measured; hydration status, weight change, activity readiness, and nutrition intake. cognitive function will be assessed on day 2, 4 and 8 of racing. one day before and one day after the race the participants will report to the lab to assess basal metabolic rate, stress via questionnaires, appetite, cognitive function, muscle biopsies, venous blood samples, mechanical efficiency and 30-min time trial.

Eligibility criteria:
inclusion criteria: * have been cycling consistently for at least 1 year before entry into the study * have been cycling for a minimum of 7 hours per week for the 6 months leading up to the study * additional for the field study: valid entry to the 2025 edition of the absa cape epic * non-smoker exclusion criteria: * do not follow a ketogenic diet or low-carbohydrate diet * have any metabolic or auto-immune disease that will influence their metabolism * take medication or supplements that is known to affect ketone supplement metabolism * suffering from a recurring injury or illness from which they have not fully recovered that is a contr-indication to perform high-intensity exercise * unable to finish each stage * women: if they are pregnant or breastfeeding

Keywords: ultra-endurance cycling physiological strain mental fatigue
oracea soolantra association in participants with severe rosacea

Conditions: Rosacea

Summary: the main objective of this study is to evaluate the efficacy of ivermectin 1% topical cream associated with doxycycline 40 mg modified release (mr) capsules versus ivermectin 1% topical cream associated with placebo in the treatment of severe rosacea.


Eligibility criteria:
inclusion criteria: * male or female subject age ≥ 18 years or older; * subject with a minimum of 20 but not more than 70 inflammatory lesions (papules and pustules) of rosacea on the face at baseline visit; * subject with severe rosacea with papulopustular lesions (according to the investigator's global assessment (iga) score rated 4); * female subjects of childbearing potential with a negative urine pregnancy test (upt); * female subjects of childbearing potential must practice a highly effective method of contraception during the study. exclusion criteria: * subjects with particular forms of rosacea or other concomitant facial dermatoses that may be confounded with rosacea; * subjects with more than 2 nodules of rosacea on the face; * subjects with any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or with optimal participation in the study or would present a significant risk to the subject; * subjects with known or suspected allergies or sensitivities to any component of the investigational and non-investigational products, including the active ingredients doxycycline and ivermectin.